Zhou Chenghao, Ding Lifeng, Wang Huailan, Li Gonghui, Gao Lei
Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Front Pharmacol. 2025 Aug 4;16:1634985. doi: 10.3389/fphar.2025.1634985. eCollection 2025.
Lactylation, a post-translational modification characterized by the attachment of lactate to protein lysine residues on proteins, plays a pivotal role in cancer progression and immune evasion. However, its implications in immunity regulation and prostate cancer prognosis remains poorly understood. This study aims to systematically examine the impact of lactylation-related genes (LRGs) on prostate cancer.
Single-cell and bulk RNA sequencing data from patients with prostate cancer were analyzed. Data were sourced from TCGA-PRAD, GSE116918, and GSE54460, with batch effects mitigated using the ComBat method. LRGs were identified from exisiting literature, and unsupervised clustering was applied to assess their prognostic siginificance. The tumor microenvironment and functional enrichment of relevant pathways were also evaluated. A prognostic model was developed using integrative machine learning techniques, with drug sensitivy analysis included. The mRNA expression profiles of the top ten genes were validated in clinical samples.
Single-cell RNA sequencing revealed distinct lactylation signatures across various cell types. Bulk RNA-seq analysis identified 56 prognostic LRGs, classifying patients into two distinct clusters with divergent prognoses. The high-risk cluster exhibited reduced immune cell infiltration and increased resistance to specific targeted therapies. A machine learning-based prognostic signature was developed, demonstrating robust predictive accuracy for treatment responses and disease outcomes.
This study offers a comprehensive analysis of lactylation in prostate cancer, identifying potential prognostic biomarkers. The proposed prognostic signature provides a novel approach to personalized treatment strategies, deepening our understanding of the molecular mechanisms driving prostate cancer and offering a tool for predicting therapeutic responses and clinical outcomes.
乳酰化是一种蛋白质翻译后修饰,其特征是乳酸与蛋白质上的赖氨酸残基结合,在癌症进展和免疫逃逸中起关键作用。然而,其在免疫调节和前列腺癌预后中的意义仍知之甚少。本研究旨在系统地研究乳酰化相关基因(LRGs)对前列腺癌的影响。
分析了前列腺癌患者的单细胞和批量RNA测序数据。数据来源于TCGA-PRAD、GSE116918和GSE54460,并使用ComBat方法减轻批次效应。从现有文献中鉴定出LRGs,并应用无监督聚类来评估其预后意义。还评估了肿瘤微环境和相关通路的功能富集情况。使用综合机器学习技术建立了一个预后模型,并进行了药物敏感性分析。对临床样本中前十个基因的mRNA表达谱进行了验证。
单细胞RNA测序揭示了不同细胞类型中独特的乳酰化特征。批量RNA-seq分析确定了56个预后LRGs,将患者分为两个预后不同的明显聚类。高风险聚类显示免疫细胞浸润减少,对特定靶向治疗的耐药性增加。开发了一种基于机器学习的预后特征,对治疗反应和疾病结果显示出强大的预测准确性。
本研究对前列腺癌中的乳酰化进行了全面分析,确定了潜在的预后生物标志物。所提出的预后特征为个性化治疗策略提供了一种新方法,加深了我们对驱动前列腺癌的分子机制的理解,并提供了一种预测治疗反应和临床结果的工具。